Living Cell Technologies (LCT)

Shares / Stock Code


Stock Exchange / Sharemarket


Living Cell Technologies (LCT) injects healthy cells to replace or repair damaged organs without the use of toxic drugs. The company targets Huntington's disease, stroke, type 1 diabetes and haemophilia. LCT's product portfolio consists of NeurotrophinCell (potential treatment of diseases of nervous system such as Huntington's disease and stroke), Fac8Cell (producing factor 8, blood clotting agent absent or defective in people suffering haemophilia) and DiabeCell (treatment of insulin-dependent diabetes).

LCT was established through a partnership between NZ entrepreneur David Collinson and Professor Elliot from the Department of Paediatrics at the University of Auckland. In 1987 Professor Elliot was in early stages of research into the use of living cells to replace/reduce the dosage of insulin for diabetic suffers. Mr Collinsons with friends invested into his research with now LCT's products close to commercialisation.

LCT differentiates itself by focusing on treatments for diseases that currently have no cure, or not being well managed. This approach puts the company in a unique position to offer alternative treatments for those diseases. Living Cell Technologies listed on the Australian stockmarket (ASX) on 1 September, 2004.

Since the company concentrates on R&D customers are minimal. Major competitors are other R&D companies involved in the industry locally and internationally trying to find cures for diseases.

Living Cell Technologies (LCT) Products and Services

  • Living Cell Technologies: developing cell-based therapies for type 1 diabetes and neurological disorders

Living Cell Technologies (LCT) Locations and Subsidiaries

Living Cell Technologies Head Office
Level 9, 20 Hunter Street, SYDNEY, NSW,
Phone: (02) 9252 1933
Fax: (02) 9235 2709

Living Cell Technologies (LCT) Share Price

Submitted by ASX Listed Company on 12 May, 2010 - 19:28